CMTM Family Proteins in Cancer Progression and Immunotherapy

The CKLF-like MARVEL transmembrane domain-containing (CMTM) family comprises a set of membrane-associated proteins that modulate intracellular signalling, membrane trafficking and immune interactions in tumours. Several CMTM members act as tumour suppressors by regulating cell cycle checkpoints, promoting apoptosis or inhibiting epithelial–mesenchymal transition, while others facilitate oncogenic signalling and therapy resistance. A defining feature of CMTM6 and related paralogues is their ability to stabilise programmed death-ligand 1 (PD-L1) on the cancer‐cell surface, thereby reinforcing immune checkpoint pathways that dampen T-cell activity. Through these dual roles—as modulators of intrinsic tumour behaviour and as extrinsic regulators of immune surveillance—CMTM proteins have emerged as promising biomarkers for disease prognosis and as targets to overcome resistance to immune checkpoint blockade. Ongoing research aims to delineate the structural determinants of CMTM–PD-L1 interaction, to map the epigenetic and post-translational networks controlling CMTM expression, and to develop small-molecule or antibody-based inhibitors that can synergise with existing immunotherapies.

Research from Nature Portfolio

No recent Nature Portfolio content available.

CMTM Family Proteins in Cancer Progression and Immunotherapy publication trend

The graph below shows the total number of articles in cmtm family proteins in cancer progression and immunotherapy across all publications each year (not limited to Nature Index journals).

Technical terms

CMTM family proteins: A group of transmembrane proteins involved in vesicle trafficking, signal transduction and immune regulation in cancer cells.

PD-L1: Programmed death-ligand 1, an immune checkpoint molecule that binds PD-1 on T cells to inhibit anti-tumour immunity.

Immune checkpoint: A regulatory pathway in the immune system that limits T-cell activation and prevents autoimmunity, but can be co-opted by tumours to evade immune attack.

Wnt/β-catenin signalling: A conserved pathway that controls cell proliferation, differentiation and migration; aberrant activation contributes to oncogenesis.

Epithelial–mesenchymal transition (EMT): A phenotypic switch where epithelial cells acquire mesenchymal traits, increasing motility and invasiveness in cancer progression.

Tumour microenvironment: The cellular and molecular milieu surrounding cancer cells, including immune cells, stroma and extracellular matrix, which influences tumour growth and therapy response.

References

1. CMTM7 inhibits breast cancer progression by regulating Wnt/β-catenin signaling. Breast Cancer Research (2023).
2. Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment. Frontiers in Oncology (2021).
3. Identifying Predictive Biomarkers for Head and Neck Squamous Cell Carcinoma Response. Cancers (2023).
4. CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers. Biochemistry and Biophysics Reports (2019).